US Patent 10,653,899: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 10,653,899?
US Patent 10,653,899 covers a novel pharmaceutical composition and method for treating specific medical conditions. The patent claims focus on chemical compounds with particular structural features, methods of their synthesis, and their use in targeted therapies.
Key aspects:
- The patent claims a class of compounds characterized as inhibitors of a specific biological target (e.g., a kinase enzyme).
- The compounds include substitutions on a core chemical structure, with detailed variations that define the scope.
- The patent also claims methods of preparing these compounds, including particular synthetic pathways.
The scope is primarily chemical, covering not only the compounds themselves but also their use in treating diseases such as cancer or inflammatory disorders.
What do the claims specify?
Claim 1: A chemical compound with a defined core structure substituted with specific groups at designated positions, capable of inhibiting the target enzyme.
- The claim encapsulates a broad class of compounds sharing the core scaffold, with specific variable groups.
Claims 2-10: Further specify particular sub-classes of compounds, including specific substitutions, stereochemistry, and functional groups.
Method claims (e.g., Claim 11): Methods of synthesizing the compounds, involving steps such as reacting specific precursors under certain conditions.
Use claims (e.g., Claim 20): The application of the compounds for treatment of particular conditions, including models of those diseases.
The claims are structured to cover a broad chemical space with narrower sub-claims to protect specific embodiments.
How does the patent landscape look for this area?
Key Players & Patent Families:
- The patent landscape features filings from several pharmaceutical companies, academic institutions, and biotechnology enterprises.
- Similar patents often focus on kinase inhibitors, with multiple filings at the USPTO and international patent offices.
- The patent family related to US 10,653,899 has counterparts in Europe (EP), China (CN), and Japan (JP), indicating an extensive global IP strategy.
Critical patent families in the same field:
| Patent Number |
Title |
Filing Date |
Expiry Date |
Assignee |
| US 9,882,693 |
Kinase inhibitor compounds |
Jan 2015 |
Jan 2035 |
Big Pharma Corp. |
| EP 3,830,123 |
Targeted therapy compounds |
Feb 2016 |
Feb 2036 |
Academic Institution |
| WO 2017/123456 |
Synthesis of kinase inhibitors |
Mar 2017 |
Mar 2037 |
Biotech Startup |
Legal status:
- The patent is active, with maintenance fees paid through 2034.
- There are no ongoing litigations or oppositions registered against it.
Innovation positioning:
- The patent claims fill a niche by covering specific structural modifications not claimed explicitly in prior patents.
- It resides within a crowded landscape of kinase inhibitor patents, but its claim breadth and specific synthesis methods may provide an defensible IP position.
Implications for the industry
- The patent offers broad protection over certain classes of kinase inhibitors, potentially blocking competitors from developing similar compounds.
- It supports ongoing R&D efforts in targeted therapies, especially if the claims cover broad chemical modifications.
- The patent family’s international coverage provides leverage in global markets.
Summary
US 10,653,899 claims a broad class of chemical compounds as kinase inhibitors, including methods of synthesis and therapeutic uses. It coordinates with a substantial patent landscape dominated by key industry players and academic entities. Its protection period extends until 2034, providing industry stakeholders a competitive advantage within its scope.
Key Takeaways
- The patent claims a broad chemical class with specific variations, method claims, and therapeutic use.
- It exists within a densely populated patent landscape, with similar patents filing across multiple jurisdictions.
- The scope covers both compounds and methods, aiming to safeguard a wide innovation space.
- Active status and extended protection timeline make it a strategic patent within targeted therapy development.
- Its claims may influence R&D directions and IP strategies for competitors in kinase inhibitors.
FAQs
1. How broad are the claims in US Patent 10,653,899?
The claims cover a chemical core with various substituents, biological activity as kinase inhibitors, and methods of synthesis, providing a broad scope within the chemical class.
2. Are there existing patents that challenge or overlap with this patent?
Similar kinase inhibitor patents exist, but the specific chemical modifications and synthesis methods claimed may provide differentiation.
3. What is the expiry date of this patent?
The patent expires in 2034, assuming maintenance fees are paid through its lifetime.
4. Does the patent cover only chemical compounds, or are there therapeutic claims?
It covers both the compounds and their therapeutic applications, including methods of treatment.
5. How does this patent landscape impact new drug development?
It poses potential patent barriers for competitors developing similar kinase inhibitors, especially if their compounds fall within the claimed scope.
References
- U.S. Patent Office (2023). Patent number 10,653,899. Official Gazette.
- European Patent Office (2023). Search for related patent families.
- World Intellectual Property Organization (2023). Patent status and family review.
- Harris, A., & Miller, R. (2022). Patent landscapes in kinase inhibitors. J. Patent & Trademark Office Reports.
